About Starsource Multitrade Limited
Data last updated:
Starsource Multitrade Limited is a public limited company based in Kalyan, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 17 August 1942, the company has been in operation for over 84 years.
Registered with ROC Mumbai under CIN L46900MH1942PLC003556. Listed on BSE: 506365.
Capital: an authorised share capital of ₹10 Cr and a paid-up capital of ₹1.5 Cr. Formerly known as Chemo Pharma Laboratories Ltd. It is led by directors including Ruchit Mehta and Sarvagya Goel.
Last AGM: 24 September 2025. Financial statements filed for year ended 31 March 2025. Office: 5 Kumud Apartment Chs Limited Karnik Road Chikan Ghar Kalyan, Maharashtra, India – 421301.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹53 Lakh. The net worth stands at ₹1.29 Cr (down 90.18% YoY). Total assets are valued at ₹1.3 Cr (down 90.11% YoY).
The company is associated with 1 brand - The Chemo Pharma Laboratories. As per MCA filings, the company has open charges of ₹50,000 and satisfied charges of ₹6.24 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website thechemopharmalaboratoriesltd.com.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address5 Kumud Apartment Chs Limited Karnik Road Chikan Ghar Kalyan, Maharashtra, India – 421301
- IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Starsource Multitrade
Starsource Multitrade has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L46900MH1942PLC003556, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L46900MH1942PLC003556 | Current |
| U99999MH1942PTC003556 | Previous |
| L99999MH1942PLC003556 | Previous |
Associated Brands with Starsource Multitrade
Starsource Multitrade operates one associated brand: The Chemo Pharma Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Bulk drugs and pharmaceuticals have been developed since 1942. | thechemopharmalaboratoriesltd.com |
Competitors & Alternatives of Starsource Multitrade
Brands and companies operating in the same space as Starsource Multitrade Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
 Laurus Labs | Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
 Symbiotec | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
 Beijing Biostar Technologies | APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
 Sterling Pharma Solutions | Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
 Provepharm Life Solutions | APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
 Hikal | APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
 Snapdragon Chemistry | Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
 SeQuent | APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
 Jubilant Pharma | Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Starsource Multitrade
The main business activity of Starsource Multitrade is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Starsource Multitrade Limited
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Board of Directors of Starsource Multitrade Limited
Starsource Multitrade has 5 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ruchit Mehta Also directs: 11Th Boulevard Films LLP, Alphatone Multitrade Limited, Sej Real Estate Private Limited and 3 more | Director | 01 Apr 2025 | 1 Years 6 Months | Current |
| Sarvagya Goel | Director | 01 Apr 2025 | 1 Years 6 Months | Current |
| Shilpy Chopra | Director | 01 Apr 2025 | 1 Years 6 Months | Current |
| Utsav Trivedi | Director | 01 Apr 2025 | 1 Years 6 Months | Current |
| Simiran Ankleshwar Tripathi | Director | 31 Dec 2024 | 1 Years 9 Months | Current |
Financials of Starsource Multitrade Limited FY 2025-26 filings available
Starsource Multitrade Limited reported revenue of ₹53 Lakh for FY 2025-26.
Financial Highlights
FY 2015-16 · ConsolidatedFinancial summary ₹ Cr
| Metrics | FY 2015-16 |
|---|---|
| Income statement | |
| Revenue | 0.00 |
| Revenue growth | +9997.0% |
| EBITDA | (1.84) |
| Profit before tax | (1.35) |
| Net profit | 0.11 |
| EPS (₹) | 0.00 |
| Balance sheet | |
| Total assets | 3.79 |
| Net worth | 3.67 |
| Total debt | 0.00 |
| Cash & bank | 0.44 |
| Net working capital | 2.12 |
| Cash flow | |
| Cash from operations | (2.09) |
| Cash from investing | 2.15 |
| Cash from financing | 0.00 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue growth | - | -38.9% | -10.0% | -50.0% | +21.2% | -32.7% | -12.5% |
| EBITDA | (11.87) | (0.11) | (0.18) | (0.20) | (0.40) | (0.33) | (0.49) |
| EBITDA margin | -2239.6% | - | - | - | - | - | - |
| Profit before tax | (11.85) | 0.50 | 1.65 | 0.08 | 0.37 | 0.32 | 0.49 |
| Net profit | 0.02 | 0.45 | 1.19 | 0.05 | 0.39 | 0.26 | 0.41 |
| Net profit margin | +3.8% | - | - | - | - | - | - |
| EPS (₹) | (79.03) | 2.28 | 8.00 | 0.32 | 3.73 | 1.67 | 2.77 |
| Balance sheet | |||||||
| Total assets | 1.30 | 13.14 | 12.80 | 11.60 | 11.55 | 10.99 | 10.74 |
| Net worth | 1.29 | 13.14 | 12.80 | 11.60 | 11.55 | 10.99 | 10.74 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.01 | 10.62 | 6.11 | 6.06 | 6.19 | 10.87 | 8.81 |
| Net working capital | 1.28 | 10.60 | 6.06 | 6.11 | 6.19 | 10.90 | 8.69 |
| Cash flow | |||||||
| Cash from operations | (10.62) | (0.28) | 0.72 | (0.68) | (0.33) | (0.41) | 4.83 |
| Cash from investing | 0.01 | 10.46 | (0.52) | 0.63 | 0.97 | (0.19) | 1.01 |
| Cash from financing | 0.00 | (0.16) | (0.15) | (0.08) | (2.12) | 1.96 | 0.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.07 | 0.00 | 0.00 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue growth (YoY) | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | (0.16) | (0.15) | 0.63 |
| Total expenses | 0.05 | 0.07 | 0.09 | 0.43 | 11.83 | 0.02 | 0.02 | 0.02 |
| EBITDA | 0.02 | (0.07) | (0.09) | 0.10 | (11.83) | (0.02) | (0.02) | (0.02) |
| EBITDA margin | +28.6% | - | - | +18.9% | - | - | - | - |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.02 | (0.07) | (0.09) | 0.10 | (11.81) | (0.18) | (0.17) | 0.61 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.00 | 0.00 |
Financial Statements
| Particulars | FY 2015-16 |
|---|---|
| Revenue | 0.00 |
| Revenue growth | +9997.0% |
| Other income | 0.49 |
| Total expenses | 1.84 |
| Employee cost | 0.03 |
| EBITDA | (1.84) |
| Depreciation | 0.00 |
| Interest | 0.00 |
| Profit before tax | (1.35) |
| Tax | 0.10 |
| Net profit | 0.11 |
| EPS (₹) | 0.00 |
| Particulars | FY 2015-16 |
|---|---|
| Equity & liabilities | |
| Share capital | 1.50 |
| Reserves & surplus | 2.17 |
| Shareholders' funds (net worth) | 3.67 |
| Minority interest | 0.00 |
| Secured loans | 0.00 |
| Unsecured loans | 0.00 |
| Total debt | 0.00 |
| Total liabilities | 3.79 |
| Assets | |
| Gross block | 0.09 |
| Net block | 0.01 |
| Capital work in progress | 0.00 |
| Investments | 0.02 |
| Inventories | 0.00 |
| Sundry debtors | 0.00 |
| Cash & bank balances | 0.44 |
| Loans & advances | 1.75 |
| Total current assets | 2.19 |
| Total current liabilities | 0.07 |
| Net working capital | 2.12 |
| Total assets | 3.79 |
| Particulars | FY 2015-16 |
|---|---|
| Opening cash | 0.38 |
| Net cash from operating activities | (2.09) |
| Net cash from investing activities | 2.15 |
| Net cash from financing activities | 0.00 |
| Net change in cash | 0.06 |
| Closing cash | 0.44 |
| Particulars | FY 2015-16 |
|---|---|
| Growth | |
| Sales growth | +9997.0% |
| EBITDA growth | +9997.0% |
| PBT growth | +9997.0% |
| Net income growth | +9997.0% |
| Profitability & leverage | |
| Return on capital employed | 0.0% |
| Return on net worth | 0.0% |
| Debt / equity | 0.00 |
| Long-term debt / equity | 0.00 |
| Interest cover | 0.00 |
| Efficiency & per share | |
| Fixed asset turnover | 0.00 |
| Inventory turnover | 0.00 |
| Debtors turnover | 0.00 |
| EPS (₹) | 0.00 |
| Dividend per share (₹) | 0.00 |
| Book value per share (₹) | 24.49 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.07 | 0.00 | 0.00 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue growth (YoY) | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | (0.16) | (0.15) | 0.63 |
| Total expenses | 0.05 | 0.07 | 0.09 | 0.43 | 11.83 | 0.02 | 0.02 | 0.02 |
| EBITDA | 0.02 | (0.07) | (0.09) | 0.10 | (11.83) | (0.02) | (0.02) | (0.02) |
| EBITDA margin | +28.6% | - | - | +18.9% | - | - | - | - |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.02 | (0.07) | (0.09) | 0.10 | (11.81) | (0.18) | (0.17) | 0.61 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue growth | - | -38.9% | -10.0% | -50.0% | +21.2% | -32.7% | -12.5% |
| Other income | 0.02 | 0.62 | 1.84 | 0.30 | 0.79 | 0.67 | 1.00 |
| Total expenses | 12.40 | 0.11 | 0.18 | 0.20 | 0.40 | 0.33 | 0.49 |
| Employee cost | 0.09 | 0.02 | 0.02 | 0.07 | 0.14 | 0.09 | 0.15 |
| EBITDA | (11.87) | (0.11) | (0.18) | (0.20) | (0.40) | (0.33) | (0.49) |
| EBITDA margin | -2239.6% | - | - | - | - | - | - |
| Depreciation | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
| Interest | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (11.85) | 0.50 | 1.65 | 0.08 | 0.37 | 0.32 | 0.49 |
| Tax | 0.00 | 0.16 | 0.44 | 0.03 | (0.20) | 0.06 | 0.08 |
| Net profit | 0.02 | 0.45 | 1.19 | 0.05 | 0.39 | 0.26 | 0.41 |
| Net profit margin | +3.8% | - | - | - | - | - | - |
| EPS (₹) | (79.03) | 2.28 | 8.00 | 0.32 | 3.73 | 1.67 | 2.77 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
| Reserves & surplus | (0.21) | 11.64 | 11.30 | 10.10 | 10.05 | 9.49 | 9.24 |
| Shareholders' funds (net worth) | 1.29 | 13.14 | 12.80 | 11.60 | 11.55 | 10.99 | 10.74 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 1.30 | 13.14 | 12.80 | 11.60 | 11.55 | 10.99 | 10.74 |
| Assets | |||||||
| Gross block | 0.02 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
| Net block | 0.00 | 0.01 | 0.01 | 0.02 | 0.04 | 0.05 | 0.08 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 4.40 | 3.03 | 2.94 | 0.04 | 0.02 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank balances | 0.01 | 10.62 | 6.11 | 6.06 | 6.19 | 10.87 | 8.81 |
| Loans & advances | 1.30 | 0.19 | 0.14 | 0.07 | 0.11 | 0.09 | 0.10 |
| Total current assets | 1.80 | 10.81 | 6.25 | 6.13 | 6.30 | 10.96 | 8.91 |
| Total current liabilities | 0.52 | 0.21 | 0.19 | 0.02 | 0.11 | 0.06 | 0.22 |
| Net working capital | 1.28 | 10.60 | 6.06 | 6.11 | 6.19 | 10.90 | 8.69 |
| Total assets | 1.30 | 13.14 | 12.80 | 11.60 | 11.55 | 10.99 | 10.74 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 10.62 | 0.61 | 0.56 | 0.69 | 2.17 | 0.81 | 2.97 |
| Net cash from operating activities | (10.62) | (0.28) | 0.72 | (0.68) | (0.33) | (0.41) | 4.83 |
| Net cash from investing activities | 0.01 | 10.46 | (0.52) | 0.63 | 0.97 | (0.19) | 1.01 |
| Net cash from financing activities | 0.00 | (0.16) | (0.15) | (0.08) | (2.12) | 1.96 | 0.00 |
| Net change in cash | (10.61) | 10.02 | 0.05 | (0.13) | (1.49) | 1.36 | 5.84 |
| Closing cash | 0.01 | 10.62 | 6.11 | 6.06 | 6.19 | 10.87 | 8.81 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% | +9997.0% |
| EBITDA growth | - | +38.9% | +10.0% | +50.0% | -21.2% | +32.7% | +12.5% |
| PBT growth | - | -69.7% | +1962.5% | -78.4% | +15.6% | -34.7% | +88.5% |
| Net income growth | -95.6% | -62.2% | +2280.0% | -87.2% | +50.0% | -36.6% | +95.2% |
| EBITDA CAGR (3Y) | +290.1% | -35.0% | -18.3% | -25.8% | -10.6% | -1.0% | +22.0% |
| Profitability & leverage | |||||||
| Net income margin | -2235.9% | - | - | - | - | - | - |
| Return on capital employed | 0.0% | +5.2% | +13.4% | +0.8% | +1.3% | +2.9% | +4.8% |
| Return on net worth | 0.0% | +3.5% | +9.8% | +0.4% | +3.4% | +2.3% | +4.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | -4.76 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 8.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 2.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (₹) | (79.03) | 2.28 | 8.00 | 0.32 | 3.73 | 1.67 | 2.77 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 8.60 | 87.63 | 85.35 | 77.35 | 77.03 | 73.30 | 71.63 |
Charges & Borrowings of Starsource Multitrade
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Apr 1990 | Bank of Baroda | ₹4.25 Cr | Satisfied |
| 01 Dec 1988 | Bank of Baroda . | ₹14.24 Lakh | Satisfied |
| 24 Feb 1988 | Bank of Baroda | ₹20 Lakh | Satisfied |
| 20 Jun 1987 | Bank of Baroda . | ₹8.6 Lakh | Satisfied |
| 28 Jun 1983 | Bank of Baroda | ₹50 Lakh | Satisfied |
Total charge records: 20 View all charges
Employees and EPFO Compliance at Starsource Multitrade
Employment history and EPFO contributions of people linked to Starsource Multitrade.
Employee and EPFO history for Starsource Multitrade Limited
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Starsource Multitrade
GST registrations and filing compliance for Starsource Multitrade Limited
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Starsource Multitrade
Credit ratings, litigation, and regulatory alerts for Starsource Multitrade Limited
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Starsource Multitrade
MSME payment history for Starsource Multitrade Limited
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Starsource Multitrade
Corporate group structure for Starsource Multitrade Limited
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Starsource Multitrade
MCA filings and documents for Starsource Multitrade Limited
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Starsource Multitrade
Recent News on Starsource Multitrade
Frequently Asked Questions about Starsource Multitrade Limited
Starsource Multitrade is an active public limited company in the pharma sector based in Kalyan, Maharashtra, India. It was incorporated on 17 August 1942 (84+ years old) and is registered under CIN L46900MH1942PLC003556. Listed on BSE: 506365.
Starsource Multitrade reported revenue of ₹53 Lakh for FY 2025-26 based on standalone financials.
The current directors of Starsource Multitrade are:
- Ruchit Mehta - Director
- Sarvagya Goel - Director
- Shilpy Chopra - Director
- Utsav Trivedi - Director
- Simiran Ankleshwar Tripathi - Director
The primary industry of Starsource Multitrade is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Starsource Multitrade is listed on BSE with code 506365.
Starsource Multitrade can be reached at the registered office: 5 Kumud Apartment Chs Limited Karnik Road Chikan Ghar Kalyan, Maharashtra, India – 421301, or through the website thechemopharmalaboratoriesltd.com.